

Assessment report on mexiletine for the treatment of recessive congenital myotonia

Summary

The Pharmaceutical Products Reimbursement Committee has approved an assessment report on the drug mexiletine for the indication recessive congenital myotonia. They reached the following conclusion:

The number of patients with recessive congenital myotonia, though small, probably exceeds 1:150,000 inhabitants of the Netherlands.

Although in the literature mexiletine is mentioned as first option in most cases, to date there is insufficient scientific clinical evidence for the efficacy of mexiletine in recessive congenital myotonia. Therefore the treatment of recessive congenital myotonia cannot be considered a rational pharmacotherapy.